Thromb Haemost 2012; 107(03): 507-512
DOI: 10.1160/TH11-08-0591
Blood Coagulation, Fibrinolysis and Cellular Hemostasis
Schattauer GmbH

Increase in the plasma levels of protein Z-dependent protease inhibitor in normal pregnancies but not in non-pregnant patients with unexplained recurrent miscarriage

Masayoshi Souri
1   Department of Molecular Patho-Biochemistry and Patho-Biology, Yamagata University School of Medicine, Yamagata Japan
,
Mayumi Sugiura-Ogasawara
2   Department of Obstetrics and Gynecology, Nagoya City University, Graduate School of Medical Sciences, Nagoya, Japan
,
Shigeru Saito
3   Department of Obstetrics and Gynecology, Toyama University, Graduate School of Medical Sciences, Toyama, Japan
,
Bettina Kemkes-Matthes
4   Haemostasis Center, Universitätsklinikum Giessen und Marburg GmbH, Marburg, Germany
,
Joost C. M. Meijers
5   Departments of Vascular Medicine and Experimental Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands
,
Akitada Ichinose
1   Department of Molecular Patho-Biochemistry and Patho-Biology, Yamagata University School of Medicine, Yamagata Japan
› Author Affiliations
Further Information

Publication History

Received: 26 August 2011

Accepted after major revision: 16 January 2011

Publication Date:
29 November 2017 (online)

Summary

Protein Z (PZ)-dependent protease inhibitor (ZPI) is a serine protease inhibitor which efficiently inactivates activated factor X, when ZPI is complexed with PZ in plasma. Reduced plasma levels of ZPI and PZ have been reported in association with thrombosis. It has also been reported that PZ increases during pregnancy and that its partial deficiency is related to early pregnancy loss or recurrent miscarriage (RM). However, until now there has been no report on ZPI in pregnancy. To explore the possible role(s) of ZPI in the maintenance of pregnancy, we studied 42 non-pregnant normal women, 32 women with normal pregnancies, and 134 cases of unexplained RM in Japan, as well as 64 non-pregnant normal German females. Plasma ZPI was measured by in-house ELISA. There were significantly higher concentrations of plasma ZPI in normal pregnancies compared to non-pregnant women. The present study also confirmed that both factor X, the major target of ZPI, and protein Z increased during normal pregnancies. This increased ZPI and PZ may counteract the increased activated factor X, which may in turn contribute to the maintenance of normal placental circulation. Plasma ZPI levels were unchanged in non-pregnant RM women, while the plasma PZ level was slightly reduced, a finding consistent with existing reports. The exact relationship between RM and this unaltered ZPI with mild PZ reduction relative to normal pregnancies warrants further investigation.

This work was presented at the 23rd International Society on Thrombosis and Haemostasis meetings in Kyoto, July 2011.

 
  • References

  • 1 Ichinose A, Takeya H, Espling E. et al. Amino acid sequence of human protein Z, a vitamin K-dependent plasma glycoprotein. Biochem Biophys Res Commun 1990; 172: 1139-1144.
  • 2 Broze Jr GJ. Protein Z-dependent regulation of coagulation. Thromb Haemost 2001; 86: 8-13.
  • 3 Tabatabai A, Fiehler R, Broze Jr GJ. Protein Z circulates in plasma in a complex with protein Z-dependent protease inhibitor. Thromb Haemost 2001; 85: 655-660.
  • 4 Han X, Fiehler R, Broze Jr GJ. Isolation of a protein Z-dependent plasma protease inhibitor. Proc Natl Acad Sci USA 1998; 95: 9250-9255.
  • 5 Han X, Fiehler R, Broze Jr GJ. Characterization of the protein Z-dependent protease inhibitor. Blood 2000; 96: 3049-3055.
  • 6 Huang X, Swanson R, Broze Jr GJ, Olson ST. Kinetic characterization of the protein Z-dependent protease inhibitor reaction with blood coagulation factor Xa. J Biol Chem 2008; 283: 29770-29783.
  • 7 Heeb MJ, Cabral KM, Ruan L. Down-regulation of factor IXa in the factor Xase complex by protein Z-dependent protease inhibitor. J Biol Chem 2005; 280: 33819-33825.
  • 8 Hemkes-Matthes B, Matthes KJ. Protein Z, a new haemostatic factor, in liver diseases. Haemostasis 1995; 25: 312-316.
  • 9 Sugawara H, Iwata H, Souri M. et al. Regulation of human protein Z gene expression by liver-enriched transcription factor HNF-4alpha and ubiquitous factor Sp1. J Thromb Haemost 2007; 05: 2250-2258.
  • 10 Han X, Huang Z F, Fiehler R. et al. The protein Z-dependent protease inhibitor is a serpin. Biochemistry 1999; 38: 11073-11078.
  • 11 Van de Water N, Tan T, Ashton F. et al. Mutations within the protein Z-dependent protease inhibitor gene are associated with venous thromboembolic disease: a new form of thrombophilia. Br J Haematol 2004; 127: 190-194.
  • 12 Refaai MA, Ahn C, Lu L. et al. Protein Z and ZPI levels and cardiovascular events. J Thromb Haemost 2006; 04: 1628-1629.
  • 13 Sofi F, Cesari F, Abbate R. et al. A meta-analysis of potential risks of low levels of protein Z for diseases related to vascular thrombosis. Thromb Haemost 2010; 103: 749-756.
  • 14 Souri M, Iwata H, Zhang WG. et al. Unique secretion mode of human protein Z: its Gla domain is responsible for inefficient, vitamin K-dependent and warfarin-sensitive secretion. Blood 2009; 113: 3857-3864.
  • 15 Dörner T, Hoppe B, Salama A. et al. Antibodies against protein Z and fetal loss: current perspectives. Clin Exp Med 2005; 05: 50-54.
  • 16 Paidas MJ, Ku DH, Langhoff-Roos J. et al. Inherited thrombophilias and adverse pregnancy outcome: screening and management. Semin Perinatol 2005; 29: 150-163.
  • 17 Sofi F, Cesari F, Tu Y. et al. Protein Z-dependent protease inhibitor and protein Z in peripheral arterial disease patients. J Thromb Haemost 2009; 07: 731-735.
  • 18 Al-Shanqeeti A, van Hylckama Vlieg A, Berntorp E. et al. Protein Z and protein Z-dependent protease inhibitor. Determinants of levels and risk of venous thrombosis. Thromb Haemost 2005; 93: 411-413.
  • 19 Forastiero RR, Martinuzzo ME, Lu L. et al. Autoimmune antiphospholipid antibodies impair the inhibition of activated factor X by protein Z/protein Z-depend-ent protease inhibitor. J Thromb Haemost 2003; 01: 1764-1770.
  • 20 Miletich J P, Broze Jr GJ. Human plasma protein Z antigen: range in normal subjects and effect of warfarin therapy. Blood 1987; 69: 1580-1586.
  • 21 Loetscher KCQ, Stiller R, Roos M. et al. Protein Z in normal pregnancy. Thromb Haemost 2005; 93: 706-709.
  • 22 Ramsay JE, Stewart F, Friel H. et al. West of Scotland PZ Study Group Protein Z in pregnancy: exaggerated rise in obese women. J Thromb Haemost 2005; 03: 2584-2586.
  • 23 Grandone E, Colaizzo D, Cappucci F. et al. Protein Z levels and unexplained fetal losses. Fertil Steril 2004; 82: 982-983.
  • 24 Bremme KA. Haemostatic changes in pregnancy. Best Pract Res Clin Haematol 2003; 16: 153-168.
  • 25 Stirling Y, Woolf L, North WRS. et al. Haemostasis in normal pregnancy. Thromb Haemost 1984; 52: 176-182.
  • 26 Zhang J, Tu Y, Lu L. et al. Protein Z-dependent protease inhibitor deficiency produces a more severe murine phenotype than protein Z deficiency. Blood 2008; 111: 4973-4978.
  • 27 Gris JC, Amadio C, Mercier E. et al. Anti-protein Z antibodies in women with pathologic pregnancies. Blood 2003; 101: 4850-4852.
  • 28 Kusanovic J P, Espinoza J, Romero R. et al. Plasma protein Z concentrations in pregnant women with idiopathic intrauterine bleeding and in women with spontaneous preterm labor. J Matern Fetal Neonatal Med 2007; 20: 453-463.
  • 29 Sater MS, Finan RR, Al-Hammad SA. et al. High Frequency of anti-protein Z IgM and IgG autoantibodies in women with idiopathic recurrent spontaneous miscarriage. Am J Reprod Immunol 2011; 65: 526-531.